NCT06849791

Brief Summary

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
9

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 24, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

February 26, 2025

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 27, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

February 24, 2026

Status Verified

February 1, 2026

Enrollment Period

1 year

First QC Date

February 24, 2025

Last Update Submit

February 23, 2026

Conditions

Healthy Volunteer

Keywords

Healthy Volunteer

Outcome Measures

Primary Outcomes (7)

  • Maximum Plasma Concentration (Cmax) of ABBV-932

    Cmax of ABBV-932

    Up to approximately 6 days

  • Time to Cmax (Tmax) of ABBV-932

    Tmax of ABBV-932

    Up to approximately 6 days

  • Terminal Phase Elimination Rate Constant (Beta) of ABBV-932

    Terminal phase elimination rate constant (beta) of ABBV-932

    Up to approximately 6 days

  • Terminal Phase Elimination Half-Life (t1/2) of ABBV-932

    Terminal phase elimination half-life of ABBV-932

    Up to approximately 6 days

  • Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932

    AUCt of ABBV-932

    Up to approximately 6 days

  • Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932

    AUCinf of ABBV-932

    Up to approximately 6 days

  • Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Up to approximately 180 days

Study Arms (8)

ABBV-932: Arm A

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.

Drug: ABBV-932

ABBV-932: Arm B

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.

Drug: ABBV-932

ABBV-932: Arm C

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.

Drug: ABBV-932

ABBV-932: Arm D

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.

Drug: ABBV-932

ABBV-932: Arm E

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.

Drug: ABBV-932

ABBV-932: Arm F

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm F on day 1 under fasting conditions.

Drug: ABBV-932

ABBV-932: Arm G

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm G on day 1 with a high-fat meal.

Drug: ABBV-932

ABBV-932: Arm H

EXPERIMENTAL

Participants will receive a single dose of ABBV-932 Arm H on day 1 under fasting conditions.

Drug: ABBV-932

Interventions

ABBV-932DRUG

Oral Capsule

ABBV-932: Arm AABBV-932: Arm CABBV-932: Arm EABBV-932: Arm FABBV-932: Arm GABBV-932: Arm H

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

You may not qualify if:

  • History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Acpru /Id# 266649

Grayslake, Illinois, 60030, United States

Location

Related Links

Study Officials

  • ABBVIE INC.

    AbbVie

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 24, 2025

First Posted

February 27, 2025

Study Start

February 26, 2025

Primary Completion

March 1, 2026

Study Completion

March 1, 2026

Last Updated

February 24, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

US(1)